MX341918B - Formulación de liposomas adecuada para tratar o prevenir la tuberculosis. - Google Patents

Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.

Info

Publication number
MX341918B
MX341918B MX2013007855A MX2013007855A MX341918B MX 341918 B MX341918 B MX 341918B MX 2013007855 A MX2013007855 A MX 2013007855A MX 2013007855 A MX2013007855 A MX 2013007855A MX 341918 B MX341918 B MX 341918B
Authority
MX
Mexico
Prior art keywords
tuberculosis
liposome
treating
therapy
formulations
Prior art date
Application number
MX2013007855A
Other languages
English (en)
Other versions
MX2013007855A (es
Inventor
Reyes Blanca
Selga Ariadna
Amat Mercè
Joan Cardona Iglesias Pere
Amat Riera Isabel
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11150072A external-priority patent/EP2471511A1/en
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of MX2013007855A publication Critical patent/MX2013007855A/es
Publication of MX341918B publication Critical patent/MX341918B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación de liposomas que comprende: (a) fragmentos de una cepa del complejo Mycobacterium tuberculosis ( MTB-C), (b) un agente formador de liposomas, 1 al 20% (peso/volumen)de sacarosa, preferentemente 2 al 12% (peso/volumen) de sacarosa, más preferentemente 3 al 8% (peso/volumen) de sacarosa, y lo más preferentemente 4 al 6% (peso/volumen) de sacarosa, en la que el tamaño promedio en z de las partículas es 120 nm o menos, en la que el tamaño promedio en z de las partículas se determina mediante dispersión de luz dinámica.
MX2013007855A 2011-01-04 2012-01-04 Formulación de liposomas adecuada para tratar o prevenir la tuberculosis. MX341918B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11150072A EP2471511A1 (en) 2011-01-04 2011-01-04 Liposome formulation suitable for treating or preventing tuberculosis
EP11183487 2011-09-30
PCT/EP2012/050080 WO2012093137A1 (en) 2011-01-04 2012-01-04 Liposome formulation suitable for treating or preventing tuberculosis

Publications (2)

Publication Number Publication Date
MX2013007855A MX2013007855A (es) 2013-10-25
MX341918B true MX341918B (es) 2016-09-07

Family

ID=45509459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007855A MX341918B (es) 2011-01-04 2012-01-04 Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.

Country Status (18)

Country Link
US (1) US9877917B2 (es)
EP (1) EP2661253B1 (es)
JP (1) JP6096675B2 (es)
KR (1) KR101820026B1 (es)
CN (2) CN103796640A (es)
BR (1) BR112013017267B1 (es)
CA (1) CA2823747C (es)
CO (1) CO6801728A2 (es)
ES (1) ES2631556T3 (es)
HU (1) HUE032409T2 (es)
IL (1) IL227338B (es)
LT (1) LT2661253T (es)
MX (1) MX341918B (es)
PL (1) PL2661253T3 (es)
RU (1) RU2648842C2 (es)
SI (1) SI2661253T1 (es)
WO (1) WO2012093137A1 (es)
ZA (1) ZA201305697B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法，及其制备的可变性脂质体
JP2016163851A (ja) * 2015-03-06 2016-09-08 国立大学法人福井大学 コンポジット型可溶化ナノリポソーム及びその製造方法
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用
WO2020206307A1 (en) * 2019-04-05 2020-10-08 Northwestern University Multi-subunit vaccines to elicit both mhc- and cd1-restricted t cell responses
WO2023062066A1 (en) * 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961412B (en) * 1995-02-22 1996-08-26 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) * 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
JP2008505106A (ja) * 2004-07-01 2008-02-21 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ハイスループットプロテオミクス
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
US20070059318A1 (en) 2005-08-15 2007-03-15 Balu-Iyer Sathy V Lipid nano particulates containing antigens as cancer vaccines
JP5806444B2 (ja) * 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
AU2006342615B8 (en) 2006-04-20 2012-07-05 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
ES2617747T3 (es) 2006-10-10 2017-06-19 Jina Pharmaceuticals Inc. Sistemas acuosos para la preparación de compuestos farmacéuticos basados en lípidos; composiciones, procedimientos y usos de los mismos
ES2307402B1 (es) * 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
BRPI0705630F8 (pt) * 2007-12-12 2022-01-18 Univ Estadual Campinas Unicamp Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma
EP2818178A1 (en) * 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
MX370744B (es) * 2009-04-24 2019-12-20 Una vacuna antituberculosis tb para evitar la reactivación.
SI2651436T1 (sl) * 2010-12-14 2016-07-29 Glaxosmithkline Biologicals S.A. Mikrobakterijski antigenski sestavek

Also Published As

Publication number Publication date
IL227338B (en) 2019-01-31
PL2661253T3 (pl) 2017-08-31
JP6096675B2 (ja) 2017-03-15
CN103796640A (zh) 2014-05-14
KR101820026B1 (ko) 2018-01-18
ES2631556T3 (es) 2017-09-01
HUE032409T2 (en) 2017-09-28
BR112013017267A2 (pt) 2018-01-09
US20150050327A1 (en) 2015-02-19
CA2823747A1 (en) 2012-07-12
ZA201305697B (en) 2014-07-30
WO2012093137A1 (en) 2012-07-12
WO2012093137A9 (en) 2012-12-27
LT2661253T (lt) 2017-05-25
CO6801728A2 (es) 2013-11-29
US9877917B2 (en) 2018-01-30
MX2013007855A (es) 2013-10-25
RU2648842C2 (ru) 2018-03-28
KR20140021538A (ko) 2014-02-20
SI2661253T1 (sl) 2017-07-31
RU2013136379A (ru) 2015-02-10
BR112013017267B1 (pt) 2021-06-22
CN107296793A (zh) 2017-10-27
EP2661253A1 (en) 2013-11-13
CA2823747C (en) 2019-07-23
JP2014501768A (ja) 2014-01-23
BR112013017267A8 (pt) 2018-11-06
IL227338A0 (en) 2013-09-30
EP2661253B1 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
MX341918B (es) Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MY165826A (en) Pharmaceutical composition
IL236123A0 (en) Preparations containing n-[4,2-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4,1-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cftr-mediated disorders
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX2011007930A (es) Conjugados de insulina cristalina.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2015DN03219A (es)
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MY161495A (en) Virus like particle compositions and methods of use
EP2581092A4 (en) AGENT IMPROVING THE METABOLISM OF LIPIDS
MX342001B (es) Tratamiento de artritis por lupus usando laquinimod.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
CL2013000785A1 (es) Compuestos 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)(-n,n-dimetilbenzamida o –n-metilbenzamida o –benzamida); composicion farmaceutica; metodo de preparacion; producto farmaceutico; metodo de tratamiento; uso para tratar un trastorno neurologico, entre otros.
EP3133073A3 (en) Inhibitors of iap
MX2016002302A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
WO2013123249A3 (en) Formulations and methods for treating ear conditions
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
EP2814491A4 (en) FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES

Legal Events

Date Code Title Description
FG Grant or registration